StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $49.79 | $50.26 | +0.94% | 3.1M |
| 05-19 | $50.42 | $51.05 | +1.25% | 3.8M |
| 05-20 | $51.14 | $50.78 | -0.70% | 2.9M |
| 05-21 | $50.84 | $51.53 | +1.36% | 2.1M |
| 05-22 | $51.56 | $51.38 | -0.35% | 3.2M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for GSK yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Fundamentals not available for GSK yet.
We pull from FMP, Finnhub, and Polygon — common gaps are very recent IPOs that haven't filed their first 10-Q, pink-sheet OTC tickers, and foreign filers without US-listed depth. The Financials tab reads SEC EDGAR directly and may still have data here.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.